Guaco (Mikania glomerata)

Guaco (Mikania glomerata) is an Amazonian herb containing coumarin compounds that may reduce respiratory inflammation through metalloprotease inhibition. Animal studies suggest it could help with bronchitis and asthma by decreasing lung oxidative stress.

Origin & History

Guaco (Mikania glomerata) is a perennial climbing vine native to South America, particularly Brazil, belonging to the Asteraceae family. It is sourced from the leaves of the plant, with extraction typically involving ethanol or hydroalcoholic methods to produce standardized extracts rich in coumarins, sesquiterpenes, diterpenes, and flavonoids.

Historical & Cultural Context

Guaco has been used in Brazilian traditional medicine (fitoterapia) for centuries to treat respiratory conditions and inflammation, and is officially recognized in Brazilian pharmacopeias as a phytotherapeutic agent. Indigenous rainforest inhabitants have historically used it for wound healing and as an antivenom for snakebites.

Health Benefits

• May reduce lung inflammation and oxidative stress (evidence from animal models only)
• Traditional use for respiratory conditions including coughs, bronchitis, and asthma (traditional evidence only)
• Potential anti-inflammatory effects through metalloprotease inhibition (preclinical evidence only)
• Historical use for wound healing applications (traditional evidence only)
• Traditional antivenom properties for snakebite treatment (traditional evidence only)

How It Works

Guaco's coumarin compounds, particularly dicoumarol derivatives, inhibit matrix metalloproteases (MMPs) that break down lung tissue during inflammation. The herb's flavonoids and phenolic acids reduce oxidative stress by scavenging free radicals and modulating inflammatory cytokines like TNF-α and IL-1β in respiratory tissues.

Scientific Research

No human clinical trials, RCTs, or meta-analyses for Mikania glomerata were identified in the research. Evidence is limited to preclinical pharmacological reviews and animal models, including rat studies showing anti-inflammatory and antioxidant effects from hydroalcoholic extracts (100 mg/kg subcutaneously) reducing lung inflammation after coal dust exposure.

Clinical Summary

Evidence for guaco comes primarily from animal studies and traditional use reports, with no published human clinical trials available. In rodent models, guaco extracts reduced lung inflammation markers by 30-50% compared to controls. Traditional practitioners report effectiveness for coughs and bronchitis, but these claims lack controlled human studies. The current evidence base is considered preliminary and requires human clinical validation.

Nutritional Profile

Guaco (Mikania glomerata) is a medicinal plant rather than a dietary staple, so nutritional macronutrient data is limited; however, its bioactive phytochemical composition is reasonably well characterized. Primary bioactive compounds include coumarin (1,2-benzopyrone) at approximately 0.1–0.5% dry weight in leaves, which is the principal marker compound used for standardization of commercial preparations. Caffeic acid derivatives are present at approximately 0.3–1.2% dry weight, including chlorogenic acid and dicaffeoylquinic acid isomers. Flavonoids including kaempferol, quercetin, and luteolin glycosides are present at approximately 0.5–2.0% dry weight total. Terpenes including friedelan-3β-ol (friedelanol), lupeol, and β-sitosterol are identified in leaf extracts. Alkaloids are absent or trace. Essential oil content is approximately 0.1–0.4% by steam distillation, containing sesquiterpenes such as germacrene-D and bicyclogermacrene. Tannins are present at low levels (~0.5–1.0% dry weight). The plant contains modest fiber content in leaf material (~15–20% dry weight as crude fiber). Vitamin content is not formally quantified but minor amounts of ascorbic acid have been noted in fresh leaf material. Mineral content includes potassium, calcium, and magnesium at concentrations typical of tropical leaf material (~10–15 mg/g dry weight combined). Bioavailability of coumarin from oral preparations is moderate; hepatic first-pass metabolism converts a significant fraction to o-hydroxyphenylacetic acid. Coumarin bioavailability varies considerably between aqueous and ethanolic extracts, with hydroalcoholic preparations yielding higher coumarin extraction efficiency.

Preparation & Dosage

No clinically studied dosage ranges for humans are available. Animal studies used hydroalcoholic extracts at 100 mg/kg subcutaneously. Standardized ethanol extracts have been analyzed containing 1.34% 2-hydroxycinnamic acid and 0.151% coumarin, but human dosing has not been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Eucalyptus, Thyme, Licorice Root, Marshmallow Root, Mullein

Safety & Interactions

Guaco contains coumarin compounds that may interact with anticoagulant medications like warfarin, potentially increasing bleeding risk. Common side effects in traditional use include mild gastrointestinal upset and skin sensitivity in some individuals. Safety during pregnancy and breastfeeding has not been established through clinical studies. Individuals with bleeding disorders should avoid guaco supplementation.